Description: Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.
High-Tech International Building
Taiyuan,
030006
China
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Lingmou Huang | Chairman & Sec. of the Board |
| Mr. Guang Zu Zhu | Gen. Mang. |
| Ms. Cheng Cheng Yang | Chief Financial Officer |
| Mr. Zhi Bo Wang | Deputy Gen. Mang. |
| Bin Yang | Deputy Gen. Mang. |
| Yulin Zhao | Board Sec. |
| Yehong Wang | Financial Controller |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 37.7797 |
| Price-to-Book MRQ: | 2.4568 |
| Price-to-Sales TTM: | 8.255 |
| IPO Date: | 1996-06-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |